Skip to main content
Year archive

Pluri Inc. — 2022 filings

All 102 regulatory filings released by Pluri Inc. (PLUR) in 2022, sourced directly from the official regulator.

102 Filings
2022 Period
2022 filings (102)
Filing Released Lang
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2022-12-30 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2022-12-30 English
Regulatory Filings 2022
Regulatory Filings
2022-12-30 English
Pluri CEO Issues Letter to Shareholders- FORM 8-K
Regulatory Filings
2022-12-29 English
Pluri CEO Issues Letter to Shareholders- FORM 8-K
Regulatory Filings
2022-12-29 English
CURRENT REPORT
Regulatory Filings
2022-12-28 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-FORM 4 -YANAY YAKY
Director's Dealing
2022-12-22 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-FORM 4 -YANAY YAKY
Director's Dealing
2022-12-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2022-12-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2022-12-22 English
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
Legal Proceedings Report
2022-12-22 English
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
Report Publication Announcement
2022-12-22 English
Director's Dealing 2022
Director's Dealing
2022-12-22 English
Director's Dealing 2022
Director's Dealing
2022-12-22 English
8K: Pluri Prices $8.2 million Private Placement Offerings
Regulatory Filings
2022-12-20 English
8K: Pluri Prices $8.2 million Private Placement Offerings
Report Publication Announcement
2022-12-20 English
CURRENT REPORT
Regulatory Filings
2022-12-19 English
Pluri Prices $8.2 million Private Placement Offerings
Capital/Financing Update
2022-12-16 English
Pluri Prices $8.2 million Private Placement Offerings
Regulatory Filings
2022-12-16 English
Form 10-Q -Sep 30, 2022 Financial Results
Interim / Quarterly Report Q1 2022
2022-11-11 English
Form 10-Q -Sep 30, 2022 Financial Results
Report Publication Announcement 9M 2022
2022-11-11 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2023
2022-11-10 English
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
Regulatory Filings
2022-11-10 English
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
Report Publication Announcement
2022-11-10 English
Pluri to Present and Participate in Upcoming Conferences
Regulatory Filings
2022-10-31 English
Pluri to Present and Participate in Upcoming Conferences
Report Publication Announcement
2022-10-31 English
FORM 8-K - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Regulatory Filings
2022-10-14 English
FORM 8-K - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Report Publication Announcement
2022-10-14 English
CURRENT REPORT
Regulatory Filings
2022-10-13 English
FORM 8-K-Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Regulatory Filings
2022-09-29 English
FORM 8-K-Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Report Publication Announcement
2022-09-29 English
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Legal Proceedings Report
2022-09-29 English
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Report Publication Announcement
2022-09-29 English
CURRENT REPORT
Regulatory Filings
2022-09-29 English
PROSPECTUS SUPPLEMENT
Share Issue/Capital Change
2022-09-22 English
PROSPECTUS SUPPLEMENT
Report Publication Announcement
2022-09-22 English
FORM 10-K-For the fiscal year ended June 30, 2022
Annual Report FY 2022
2022-09-22 English
FORM 10-K-For the fiscal year ended June 30, 2022
Report Publication Announcement
2022-09-22 English
424B5
Prospectus
2022-09-21 English
ANNUAL REPORT
Annual Report FY 2022
2022-09-21 English
€7.5 Million Granted to Collaborative PROTO Project led by Charit? to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
Regulatory Filings
2022-09-06 English
€7.5 Million Granted to Collaborative PROTO Project led by Charit? to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
Regulatory Filings
2022-09-06 English
Following our circular regarding the company's name change, the ISIN was changed to US72924G1040
Regulatory Filings
2022-07-28 Hebrew (modern)
Immediate Report about Change of Name -PLURI INC
Regulatory Filings
2022-07-26 English
Changes in company's name: PLURI INC
Regulatory Filings
2022-07-25 Hebrew (modern)
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Regulatory Filings
2022-07-25 English
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Report Publication Announcement
2022-07-25 English
Pluri CEO Issues Shareholder Update
Regulatory Filings
2022-07-25 English
Pluri CEO Issues Shareholder Update
Report Publication Announcement
2022-07-25 English
CURRENT REPORT
Regulatory Filings
2022-07-25 English
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Regulatory Filings
2022-07-25 English
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Report Publication Announcement
2022-07-25 English
FORM 8-K-e results from its Phase III Study of muscle regeneration following hip fracture surgery
Regulatory Filings
2022-07-13 English
FORM 8-K-e results from its Phase III Study of muscle regeneration following hip fracture surgery
Report Publication Announcement
2022-07-13 English
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Earnings Release Q2 2022
2022-07-13 English
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Report Publication Announcement
2022-07-13 English
CURRENT REPORT
Regulatory Filings
2022-07-13 English
Results of the Annual Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements
2022-06-24 English
Results of the Annual Meeting of Shareholders
Regulatory Filings
2022-06-24 English
CURRENT REPORT
Regulatory Filings
2022-06-23 English
Form 10-Q-FOR THE QUARTERY PERIOD ENDED March 31,2022
Interim / Quarterly Report 9M 2022
2022-05-10 English
Form 10-Q-FOR THE QUARTERY PERIOD ENDED March 31,2022
Report Publication Announcement Q1 2022
2022-05-10 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2022
2022-05-09 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On June 21, 2022
Proxy Solicitation & Information Statement
2022-04-28 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On June 21, 2022
AGM Information
2022-04-28 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2022-04-27 English
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Regulatory Filings
2022-03-28 English
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Report Publication Announcement
2022-03-28 English
Pluristem Releases PLX-R18 Hematology Phase I Study Results
Regulatory Filings
2022-03-24 English
Pluristem Releases PLX-R18 Hematology Phase I Study Results
Report Publication Announcement
2022-03-24 English
CURRENT REPORT
Regulatory Filings
2022-03-24 English
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Earnings Release Q1 2022
2022-03-23 English
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Report Publication Announcement
2022-03-23 English
8K:Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Regulatory Filings
2022-03-08 English
8K:Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Report Publication Announcement
2022-03-08 English
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Board/Management Information
2022-03-08 English
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Report Publication Announcement
2022-03-08 English
CURRENT REPORT
Regulatory Filings
2022-03-08 English
Pluristem CEO Issues Shareholder Update
Investor Presentation
2022-03-02 English
Pluristem CEO Issues Shareholder Update
Report Publication Announcement
2022-03-02 English
FORM 8-K-Closing of the previously announced agreements with Tnuva Food Industries
Regulatory Filings
2022-02-28 English
FORM 8-K-Closing of the previously announced agreements with Tnuva Food Industries
Report Publication Announcement
2022-02-28 English
CURRENT REPORT
Regulatory Filings
2022-02-28 English
Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
M&A Activity
2022-02-24 English
Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
Report Publication Announcement
2022-02-24 English
Form 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Aberman Zami
Director's Dealing
2022-02-15 English
Form 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Aberman Zami
Director's Dealing
2022-02-15 English
Director's Dealing 2022
Director's Dealing
2022-02-14 English
Form 10-Q-FOR THE QUARTERY PERIOD ENDED December 31,2021
Interim / Quarterly Report H1 2022
2022-02-08 English
Form 10-Q-FOR THE QUARTERY PERIOD ENDED December 31,2021
Report Publication Announcement
2022-02-08 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2022
2022-02-07 English
SCHEDULE 13G
Major Shareholding Notification
2022-01-26 English
8K: the Company ’s and Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform-the correction file attacht
Regulatory Filings
2022-01-10 English
8K: the Company ’s and Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform-the correction file attacht
Report Publication Announcement
2022-01-10 English
8K: the Company ’s and Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform-the attacht is incorrect. a correction will be published
Regulatory Filings
2022-01-10 English
8K: the Company ’s and Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform-the attacht is incorrect. a correction will be published
Report Publication Announcement
2022-01-10 English
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
Regulatory Filings
2022-01-10 English
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
Report Publication Announcement
2022-01-10 English
CURRENT REPORT
Regulatory Filings
2022-01-10 English
FORM 8-K: CONSULTING AGREEMENT with Mr. Zalman (Zami) Aberman, the Company’s Chairman of the Board of Directors
Regulatory Filings
2022-01-04 English
FORM 8-K: CONSULTING AGREEMENT with Mr. Zalman (Zami) Aberman, the Company’s Chairman of the Board of Directors
Report Publication Announcement
2022-01-04 English
CURRENT REPORT
Regulatory Filings
2022-01-03 English